^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib
Published date:
07/31/2020
Excerpt:
We established the KNZ osimertinib-resistant (KNZ_OR) tumor cell line with MET amplification using a cervical spine lesion that was intrinsically resistant to osimertinib...Combination with osimertinib plus crizotinib induced tumor shrinkage in the KNZ_OR xenograft model...
DOI:
10.1111/cas.14593
